Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective
Frontiers in Pediatrics · 19.02.2026 · 14
DOI: 10.3389/fped.2026.1676689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 19.02.2026. Verfasst von Stefania Tonetto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
The 2024–2025 winter season was the first in which Nirsevimab was adopted as universal prophylaxis for bronchiolitis in Friuli Venezia Giulia, a region in the northeastern Italy. This report describes the impact of Nirsevimab universal prophylaxis on bronchiolitis from the perspective of a tertiary-level, children's hospital, the Institute IRCCS Burlo Garofolo in Trieste, Italy.
Methods
We conducted a retrospective observational study reviewing the medical records of all children diagnosed with bronchiolitis during the 2024–2025 winter season, and the winter seasons of the seven preceding years. For each infant admitted, we collected data on age, gender, viral testing result, the need for ventilatory support, and the length of hospital stay. The primary outcome was the number of infant admissions for bronchiolitis during the 2024–2025 winter season, compared with previous years.
Results
During the study period, from 2016 to 2025, 695 infants were diagnosed with bronchiolitis, and 195 were hospitalized. In the 2024–2025 winter season, 597 neonates, 94% of the children born at the Institute, received Nirsevimab prophylaxis. Following the introduction of Nirsevimab, we observed a drastic decrease in the number of infants requiring hospitalization, a marked reduction in infants needing ventilatory support, and a considerable decrease in the cumulative length of hospital stay for bronchiolitis, compared to previous years. These results were clearly related to a substantial decrease in the number of RSV-positive infants arrived at the Institute.
Discussion
In our population, Nirsevimab prophylaxis was very effective and led to a considerable reduction in the number of infants infected with RSV and requiring hospitalization. The hospital burden of bronchiolitis was significantly reduced.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
- Department of Advanced Translational Microbiology, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
- Department of Health Prevention, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
- Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy.
- Central Directorate for Health, Social Policies, Friuli Venezia Giulia Region, Trieste, Italy.
- Department of Medical Sciences, University of Trieste, Trieste, Italy.
Zitieren
APA
Tonetto, S., Cason, C., Fasiolo, E., Dal Cin, M., Cozzi, G., Giangreco, M., Zappetti, C., Nider, S., Amaddeo, A., Comar, M., & Travan, L. (2026). Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1676689
Vancouver
Tonetto S, Cason C, Fasiolo E, Dal Cin M, Cozzi G, Giangreco M, et al. Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1676689
BibTeX
@article{Tonetto2026,
author = {Tonetto, Stefania and Cason, Carolina and Fasiolo, Elena and Dal Cin, Margherita and Cozzi, Giorgio and Giangreco, Manuela and Zappetti, Cristina and Nider, Silvia and Amaddeo, Alessandro and Comar, Manola and Travan, Laura},
title = {Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1676689}
}
EUVIMED